The Goldman Sachs Group Lowers Baxter International (NYSE:BAX) Price Target to $22.00

Baxter International (NYSE:BAX) had its price objective reduced by equities researchers at The Goldman Sachs Group from $25.00 to $22.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical instruments supplier’s stock. The Goldman Sachs Group’s price target would indicate a potential upside of 19.14% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on the company. Argus cut Baxter International from a “buy” rating to a “hold” rating in a research note on Friday. Stifel Nicolaus restated a “hold” rating and set a $25.00 target price (down previously from $36.00) on shares of Baxter International in a research note on Monday, August 4th. Evercore ISI decreased their target price on Baxter International from $31.00 to $24.00 in a research note on Thursday. Wall Street Zen cut Baxter International from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Finally, Barclays decreased their target price on Baxter International from $41.00 to $36.00 and set an “overweight” rating for the company in a research note on Monday, August 4th. Two investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $23.70.

Baxter International Stock Performance

Shares of BAX opened at $18.47 on Friday. The stock has a 50-day simple moving average of $23.14 and a 200-day simple moving average of $26.85. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.49 and a current ratio of 2.30. The stock has a market capitalization of $9.48 billion, a PE ratio of -61.55, a PEG ratio of 0.73 and a beta of 0.58. Baxter International has a 1 year low of $18.42 and a 1 year high of $37.74.

Baxter International (NYSE:BAX) last announced its quarterly earnings data on Thursday, October 30th. The medical instruments supplier reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.09. The business had revenue of $2.84 billion during the quarter, compared to analysts’ expectations of $2.88 billion. Baxter International had a positive return on equity of 16.96% and a negative net margin of 1.42%.The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.80 EPS. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS. FY 2025 guidance at 2.350-2.400 EPS. On average, analysts predict that Baxter International will post 2.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Zions Bancorporation National Association UT acquired a new position in Baxter International during the first quarter worth approximately $27,000. CoreFirst Bank & Trust acquired a new position in Baxter International during the second quarter worth approximately $27,000. Rossby Financial LCC acquired a new position in Baxter International during the first quarter worth approximately $29,000. Creative Financial Designs Inc. ADV increased its position in Baxter International by 169.6% during the second quarter. Creative Financial Designs Inc. ADV now owns 984 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 619 shares during the period. Finally, MTM Investment Management LLC acquired a new position in Baxter International during the second quarter worth approximately $30,000. Institutional investors and hedge funds own 90.19% of the company’s stock.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.